TRIANA Biomedicines

TRIANA Biomedicines

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://www.trianabio.com

Last Round

Series B

Dec 3, 2025

Total Funding Raised

$350M

Momentum Score

50 /100

Company Overview

TRIANA Biomedicines is a biotechnology company focused on discovering and developing molecular glues that stabilize protein interactions to enhance therapeutic options for various diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

molecular gluestargeted protein degradationTPDmolecular glue discoverydrug discovery platformprotein degradersdegrader discoveryundruggable proteinsAI drug discoverysmall molecule therapeuticsrational drug designinduced proximityoncology therapeuticscomputational drug discoveryE3 ligase selectionpharma partnershipsdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TRIANA Biomedicines Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TRIANA Biomedicines Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BDec 3, 2025
Series BDec 3, 2024
Series AApr 6, 2022

Key People

Founding team and executive leadership

Patrick Trojer

Chief Executive Officer President

Executive Team

TRIANA Biomedicines Investors

Notable investors and investment history

InvestorRounds
RA Capital ManagementSeries B, Seed, Series A
Finchley Healthcare VenturesSeries B
Regeneron VenturesSeries B
Logos CapitalSeries A
AccompliceSeries B
Surveyor CapitalSeries B, Series A
Pfizer VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 149% MoM, reaching 6.2K.

  • Apr 15, 2026

    Presenting candidate TRI-611 at AACR Annual Meeting 2026.

TRIANA Biomedicines Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TRIANA Biomedicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TRIANA Biomedicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range58
Year Founded2021
Last FundingDec 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.